LAVA Therapeutics (NASDAQ:LVTX) Sees Significant Increase in Short Interest

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 58,700 shares, a growth of 178.2% from the November 30th total of 21,100 shares. Based on an average daily volume of 89,100 shares, the short-interest ratio is presently 0.7 days. Currently, 0.4% of the company’s stock are sold short.

LAVA Therapeutics Stock Performance

Shares of NASDAQ:LVTX traded up $0.00 during trading hours on Friday, hitting $0.99. The stock had a trading volume of 253,037 shares, compared to its average volume of 515,669. The stock’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.73. The firm has a market capitalization of $25.18 million, a price-to-earnings ratio of -0.96 and a beta of 0.43. LAVA Therapeutics has a 1-year low of $0.88 and a 1-year high of $6.47.

Institutional Trading of LAVA Therapeutics

Several large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new stake in shares of LAVA Therapeutics during the 2nd quarter worth about $55,000. Virtu Financial LLC bought a new stake in LAVA Therapeutics during the third quarter worth approximately $32,000. Finally, Pathway Financial Advisors LLC lifted its position in LAVA Therapeutics by 70.8% in the third quarter. Pathway Financial Advisors LLC now owns 102,500 shares of the company’s stock worth $170,000 after purchasing an additional 42,500 shares during the period.

Analysts Set New Price Targets

LVTX has been the subject of several research reports. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Leerink Partnrs lowered shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 12th. JMP Securities restated a “market perform” rating and issued a $6.00 target price on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Finally, HC Wainwright reduced their price objective on LAVA Therapeutics from $6.00 to $2.00 and set a “buy” rating for the company in a research report on Friday, December 20th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.33.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.